Literature DB >> 26189907

A case of intrahepatic cholangiocarcinoma detected after successful interferon therapy for chronic hepatitis C.

Hiroji Shinkawa1, Seikan Hai2, Hiromu Tanaka2, Shigekazu Takemura3, Kazuki Ohba3, Takahiro Uenishi3, Shintaro Kodai3, Yorihisa Urata3, Kazuhisa Kaneda3, Masayuki Sakae3, Kenichi Wakasa4, Shoji Kubo3.   

Abstract

A 65-year-old man presented at our hospital in 2006 because of a liver tumor. He had been treated for chronic hepatitis C with interferon-α2b for 6 months in 1998. A pathological examination showed that the hepatic tissue before interferon (IFN) therapy was classified as moderately active hepatitis with severe hepatic fibrosis. The IFN therapy induced the disappearance of the hepatitis C virus (HCV) RNA from his serum and normalized alanine aminotransferase activity. In 2005, a tumor (2 cm in diameter) was detected in the right lobe of the liver by ultrasonography and computed tomography, and the tumor was stained with contrast medium during abdominal angiography. A right lobectomy was performed under the diagnosis of hepatocellular carcinoma. The pathological examination revealed that the tumor was an intrahepatic cholangiocarcinoma (ICC). The noncancerous hepatic tissue was classified as having minimal activity with mild fibrosis. It is important to monitor closely for ICC as well as hepatocellular carcinoma even patients in whom the HCV RNA has disappeared after IFN therapy, because the outcome of treatment for small ICC is favorable.

Entities:  

Keywords:  Hepatitis C virus; Interferon therapy; Intrahepatic cholangiocarcinoma; Sustained virologic response

Year:  2009        PMID: 26189907     DOI: 10.1007/s12328-009-0128-2

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  26 in total

1.  Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma.

Authors:  T Uenishi; K Hirohashi; S Kubo; T Yamamoto; O Yamazaki; H Kinoshita
Journal:  Br J Surg       Date:  2001-07       Impact factor: 6.939

2.  Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.

Authors:  Takahiro Uenishi; Shoji Kubo; Kazuhiro Hirohashi; Hiromu Tanaka; Taichi Shuto; Takatsugu Yamamoto; Akihiro Tamori; Seikan Hai; Hiroaki Kinoshita; Shuhei Nishiguchi
Journal:  Hepatol Res       Date:  2002-12       Impact factor: 4.288

3.  Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma.

Authors:  Satoshi Yamamoto; Shoji Kubo; Seikan Hai; Takahiro Uenishi; Takatsugu Yamamoto; Taichi Shuto; Shigekazu Takemura; Hiromu Tanaka; Osamu Yamazaki; Kazuhiro Hirohashi; Takashi Tanaka
Journal:  Cancer Sci       Date:  2004-07       Impact factor: 6.716

4.  Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus.

Authors:  Akihiro Tamori; Takehiro Hayashi; Mayumi Shinzaki; Sawako Kobayashi; Shuji Iwai; Masaru Enomoto; Hiroyasu Morikawa; Hiroki Sakaguchi; Susumu Shiomi; Shigekazu Takemura; Shoji Kubo; Norifumi Kawada
Journal:  J Med Virol       Date:  2009-06       Impact factor: 2.327

5.  Minute nodular intrahepatic cholangiocarcinoma.

Authors:  M Yamamoto; K Takasaki; M Nakano; A Saito
Journal:  Cancer       Date:  1998-06-01       Impact factor: 6.860

6.  Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.

Authors:  Ji Y Kim; Myung-Hwan Kim; Tae Y Lee; Chang Y Hwang; Jae S Kim; Sung-Cheol Yun; Sang S Lee; Dong W Seo; Sung K Lee
Journal:  Am J Gastroenterol       Date:  2008-01-02       Impact factor: 10.864

7.  Intrahepatic peripheral cholangiocarcinoma: two-phased dynamic incremental CT and pathologic correlation.

Authors:  H Honda; H Onitsuka; K Yasumori; T Hayashi; K Ochiai; M Gibo; E Adachi; T Matsumata; K Masuda
Journal:  J Comput Assist Tomogr       Date:  1993 May-Jun       Impact factor: 1.826

8.  Clinicopathologic characteristics of hepatitis C virus-associated intrahepatic cholangiocarcinoma.

Authors:  Seikan Hai; Shoji Kubo; Satoshi Yamamoto; Takahiro Uenishi; Hiromu Tanaka; Taichi Shuto; Shigekazu Takemura; Osamu Yamazaki; Kazuhiro Hirohashi
Journal:  Dig Surg       Date:  2006-02-10       Impact factor: 2.588

9.  Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

Authors:  Y Imai; S Kawata; S Tamura; I Yabuuchi; S Noda; M Inada; Y Maeda; Y Shirai; T Fukuzaki; I Kaji; H Ishikawa; Y Matsuda; M Nishikawa; K Seki; Y Matsuzawa
Journal:  Ann Intern Med       Date:  1998-07-15       Impact factor: 25.391

10.  Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors:  S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.